The Effectiveness and Safety of Bushen Huoxue Decoction on Treating Coronary Heart Disease: A Meta-Analysis.
The Effectiveness and Safety of Bushen Huoxue Decoction on Treating Coronary Heart Disease: A Meta-Analysis.
复制标题
DOI：
10.1155/2021/5541228
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Wang J
中科院分区：
文献类型：
--
作者：
Liu LC;Mao QY;Liu C;Hu J;Duan L;Wang J
本研究旨在系统评价中药复方补肾活血汤治疗冠心病的有效性和安全性。 计算机检索PubMed、科克伦图书馆、中国知网、万方、SinoMed、维普等6个数据库，检索截止2020年3月有关补肾活血汤治疗冠心病的随机对照试验。本研究使用科克伦手册中的科克伦风险检验偏倚工具来评估方法学的质量。使用Review Manager（RevMan）5.3分析结果。采用建议评估、发展和评价分级（GRADE）标准对证据质量进行分类。 10项随机对照试验共纳入901例患者。结果表明，补肾活血汤治疗冠心病的疗效明显优于西药常规治疗（P < 0.00001）。补阳还五汤治疗组对心电图的有效率也明显高于西药组（P < 0.00001）。治疗组低密度脂蛋白胆固醇较对照组降低（P < 0.00001）。心绞痛发作频率和持续时间也减少（P < 0.00001）。治疗组与对照组之间TC水平（P=0.08）、TG水平（P=0.86）和HDL水平（P=0.76）无显著性差异。五项研究报告了不良事件，包括恶心和腹泻。 本研究结果为补肾泻心汤联合常规西药治疗冠心病奠定了基础。但由于纳入研究质量的限制，加上潜在的报告偏倚，上述结论仍需更高质量和更好设计的研究来验证。
The aim of this meta-analysis was to systematically evaluate the effectiveness and safety of the traditional Chinese medicine (TCM) formula Bushen Huoxue Decoction (BSHXD) in treating coronary heart disease (CHD). Randomized controlled trials (RCTS) of BSHXD in treating CHD were searched until March 2020, through six electronic databases: PubMed, Cochrane Library, CNKI, WanFang, SinoMed, and VIP. This study used the Cochrane Risk Test bias tool in the Cochrane Handbook to assess the quality of the methodology. Review Manager (RevMan) 5.3 was used to analyze the results. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria were applied in the classification of evidence quality. Ten RCTs involving 901 patients were finally included in this meta-analysis. It revealed that the effectiveness of BSHXD in treating CHD was significantly better than that of the conventional western medicine (CWM) treatment (P < 0.00001). The effective rate of BSHXD treatment group on ECG was also significantly higher than that of CWM group (P < 0.00001). The low-density lipoprotein cholesterol was decreased in the treatment groups compared with those in the control groups (P < 0.00001). There was also a reduction in frequency and duration of angina pectoris (P < 0.00001). There were no significant differences in TC level (P=0.08), TG level (P=0.86), and HDL level (P=0.76) between the treatment and control groups. Five studies had informed adverse events, including nausea and diarrhea. Our findings laid the foundation to the use of TCM Formula BSHXD in combination with conventional western medicine for treating CHD. However, due to the limitation of the quality of the included researches, in addition to potential reporting bias, the above conclusions still need verification by higher-quality and better-designed studies.
登录
查看更多内容
影响因子：
39.2
作者：
Moher, David;Liberati, Alessandro;Altman, Douglas G.
通讯作者：
Altman, Douglas G.
影响因子：
19.6
作者：
Culleton, BF;Larson, MG;Levy, D
通讯作者：
Levy, D
影响因子：
24
作者：
Wolk, Michael J.;Brindis, Ralph G.
通讯作者：
Brindis, Ralph G.
影响因子：
39.2
作者：
Mann, JFE;Gerstein, HC;Yusuf, S
通讯作者：
Yusuf, S
影响因子：
13.2
作者：
FLACK, JM;NEATON, JD;ESUNGE, P
通讯作者：
ESUNGE, P